Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2020

View Archived Issues

SARS-CoV-2 requires ACE2 and TMPRSS2 for cell entry, which may be blocked by a TMPRSS2 inhibitor

Mitochondria-related miR-4485-3p is underexpressed in idiopathic asthenozoospermia

ChAdOx1 nCoV-19 vaccine candidate enters clinical testing

Oryzon to initiate phase II ESCAPE study of vafidemstat in severely ill COVID-19 patients in Spain

Promising data for COVID-19 patients with ARDS treated with remestemcel-L

MMP12 as a novel target for post-stroke neurological recovery

TNIK is a novel druggable target in LSCC with 3q amplification

Edited stem cells reverse mouse diabetes

Noncoding TET2 variants affect neurodegeneration risk

Ichnos Sciences describes new MAP4K1 inhibitors

New menin/MLL interaction inhibitors patented by University of Michigan, Agios Pharmaceuticals

Genentech, Roche present IL-2 secretion inducers

SiteOne Therapeutics identifies Nav1.7 channel blockers

Sloan-Kettering Institute for Cancer Research, Tri-I TDI identify PI3K-alpha inhibitors

Flu study links metabolic changes to cytokine storm

AGTR1 and aromatase are potential therapeutic targets in glioblastoma

SAGE-324 generally well tolerated in essential tremor patients, phase II study planned

Polyneuron receives European clearances for phase I/IIa study of PN-1007 in anti-MAG neuropathy

Lilly begins phase II study of LY-3127804 in COVID-19

Hyundai studies BPDO-1603 in phase III for moderate to severe Alzheimer's disease

Hua reports phase I data on dorzagliatin with empagliflozin in type 2 diabetes

Phase III study of Libtayo in first-line NSCLC meets OS primary endpoint

Avadel reports pivotal phase III data on FT-218 in patients with narcolepsy

New phase III trial to evaluate pacritinib in patients with severe COVID-19

Preliminary findings from phase II portion of U.S. phase II/III trial of Kevzara in COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...